Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 9/20 | 0.76 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.76 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9668837 | 1.00 | AKR1B1 (0.76) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL8313631 | 0.88 | AKR1B1 (0.74) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL9667246 | 0.87 | AKR1B1 (0.69) | AKR1B1AKR1B10AKR1A1MAPT | |
| (R,S)-Fidarestat SCHEMBL48828 | 0.86 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1MAPT | |
| (R,S)-Fidarestat SCHEMBL1219758 | 0.86 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1MAPT | |
| Fidarestat SCHEMBL48827 | 0.86 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1MAPT | |
| (R,S)-Fidarestat SCHEMBL29941924 | 0.86 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1MAPT | |
| (R,S)-Fidarestat SCHEMBL2855039 | 0.86 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL8311471 | 0.86 | AKR1B1 (0.83) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL9250816 | 0.86 | AKR1B1 (0.83) | AKR1B1AKR1B10AKR1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0485219-A2 | Medicaments for preventing and treating circulatory organ diseases containing spiro-3-heteroazolidine compounds | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1992-05-13 | — | — | EP | disclosed |